Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 23, 2022 07:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech to Present at 5th Annual Evercore ISI HealthCONx Conference

PITTSBURGH, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients...
November 17, 2022 07:00 ET | Source: Krystal Biotech, Inc.

Jeune Aesthetics Announces Positive Durability Results for KB301 in the PEARL-1 Extension Cohort, an Investigational Gene-based Treatment for Improvement of Fine Lines and Wrinkles

Up to nine months durability of effect observed in patients aged 55 to 76 in the extension cohort following administration of high dose KB301Mean change in Subject Satisfaction Scores from baseline...
November 07, 2022 07:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Announces Third Quarter 2022 Financial Results and Operational Highlights

• Received US FDA filing acceptance of B-VEC BLA with Priority Review designation for treatment of dystrophic epidermolysis bullosa; PDUFA target action date of February 17, 2023 • Notified of no...
September 29, 2022 07:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech to Present at Chardan’s 6th Annual Genetic Medicines Conference

PITTSBURGH, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the...
September 22, 2022 18:32 ET | Source: Krystal Biotech, Inc.

Krystal Biotech erhält positive Stellungnahme des Pädiatrieausschusses der EMA hinsichtlich des pädiatrischen Prüfkonzepts für B-VEC bei der Behandlung von dystropher Epidermolysis bullosa

• Das Unternehmen befindet sich im Zeitplan, um im vierten Quartal 2022 einen Zulassungsantrag für Europa zu stellen • Es sind keine weiteren Studien erforderlich PITTSBURGH, Sept. 23, 2022...
September 22, 2022 18:32 ET | Source: Krystal Biotech, Inc.

Krystal Biotech reçoit un avis positif de la part du Comité pédiatrique de l'EMA pour son plan d'investigation pédiatrique sur B-VEC pour le traitement de l'épidermolyse bulleuse dystrophique

• La Société est sur la bonne voie pour soumettre sa demande de mise sur le marché européen au 4e trimestre 2022 • Aucune étude supplémentaire n'est requise PITTSBURGH, 23 sept. 2022 (GLOBE...
September 21, 2022 16:30 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for B-VEC for the treatment of Dystrophic Epidermolysis Bullosa

• Company on track to submit European marketing application in Q4 2022 • No additional studies required PITTSBURGH, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”)...
September 08, 2022 07:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech to Present at H.C. Wainwright 24th Annual Global Investment Conference

PITTSBURGH, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the...
August 18, 2022 17:00 ET | Source: Krystal Biotech, Inc.

FDA Accepts Krystal Biotech’s Biologics License Application for Dystrophic Epidermolysis Bullosa

FDA granted Priority Review designationPDUFA target action date is February 17, 2023FDA stated that it is not currently planning to hold an advisory committee meeting PITTSBURGH, Aug. 18, 2022 ...
August 08, 2022 07:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Announces Second Quarter 2022 Financial Results and Reports Updates on Operational Progress

Biologics License Application for B-VEC filed with the FDA on June 22, 2022FDA accepts IND on KB407 for the treatment of Cystic FibrosisStrong balance sheet, closing the quarter with $438.5 million in...